Fujifilm is helping make the world a better, healthier, and more interesting place. Learn more about what we’re about.
FUJIFILM Diosynth Biotechnologies, and FUJIFILM Manufacturing Europe will present its comprehensive technologies and solutions for the global biopharmaceutical and regenerative medicine industry at BIO EUROPE 2017, Europe’s largest life science partnering conferences, supported by the Biotechnology Innovation Organisation (BIO) held November 6-8, 2017 at CityCube Berlin, Germany. The company will also offer two educational session focused on “Regenerative medicine: new revolutionary injectable microcarrier” and “New generation of CDMO development and manufacturing solutions”.
Healthcare has become one of the world’s most important industries. Moreover, today people expect treatments and drugs to do more than merely cure pathologies; they are looking for higher quality of life overall. To meet the needs of this new era, Fujifilm has evolved into a comprehensive healthcare company, offering products in the fields of diagnosis, prevention and treatment. Founded in 1934, the company entered into medical business in 1936 releasing X-ray films. During the informatics and the digital revolution, Fujifilm pioneered the world’s first digital X-ray system and the world’s first web-based image management solution. Nowadays, the company is world leader in cGMP CDMO, supporting partners in the biopharmaceutical industry with the development and production of biology and vaccine candidates, and focuses on unmet medical needs by leveraging the power of iPS cells to develop advanced treatment modality.
At Bio Europe 2017 Fujifilm brings together for the first time the ultimate solutions of Fujifilm Diosynth Biotechnologies and Fujifilm Manufacturing Europe to maximise value offered to potential partners and make a step ahead in a new era of patient-centric care.
Fujifilm Diosynth Biotechnologies - A world leading Cgmp Contract Development and Manufacturing Organization on providing solutions to deliver biotherapeutics and advanced therapies, in the area of monoclonal antibody process development and manufacturing services.
Fujifilm Regenerative medicine - Represented by Fujifilm Manufacturing Europe/R&D laboratory in Tilburg, that developed an artificial biomaterial based on human collagen type I. This recombinant polypeptide, commercially available under the name Cellnest, enhances cell attachment making it particularly suitable as matrix for cell culturing and tissue engineering in regenerative medicine. At Bio Europe 2017, a new formulation of RCP will be presented.
For over 80 years Fujifilm has continually invested in research and development, resulting in world-class highly versatile fundamental core technologies. Fujifilm intends to make available these technologies to meet the ever growing demand of care and health all over the world.
Regenerative Medicine: New revolutionary injectable microcarrier - on Tuesday, November 7th from 9.30 in Room M6, Level Level 3. Presenter: Peter Van Asten, R&D manager Life Science Fujifilm Manufacturing Europe, Tilburg The Netherlands.
Development solutions and Partnering Platforms: New generation of CDMO development and manufacturing solutions - on Tuesday, November 7th from 11.15 in Room M2, Level Level 3. Presenter: Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies
Fujifilm Corporation is a wholly-owned subsidiary of Fujifilm Holdings Corporation.